David Clark is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Hayden Bridge Way
Springfield, OR 974771347
Telephone
541-868-9430Provider last certified this registry record 13 May 2021.
Clinical trials
- Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults
Sponsor: University of Florida
- Balance After Traumatic Brain Injury
Sponsor: VA Office of Research and Development
- Management and Outcomes Following Emergency Surgery for Traumatic Brain Injury
Sponsor: University of Cambridge
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
39 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TG Therapeutics, Inc.Program year202538 payments$54,712openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202548 payments$40,190openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year202550 payments$36,247openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
86.2%Neuromuscular Blocker84.7%Onabotulinumtoxina100%Botox0%Part D + Part B<11 patientsgamma-Aminobutyric Acid-ergic Agonist1%Baclofen100%Part D≥49 patients+ 2 more classes in this area
Nervous system
9.4%Gabapentinoids1.9%Gabapentin84%Pregabalin13%Lyrica3%Part D<11 patientsCholinesterase Inhibitor1.1%Pyridostigmine Bromide74%Donepezil Hcl26%Part D≥48 patients+ 19 more classes in this area
Cancer & immunology
2.6%Other immunosuppressants0.7%Vumerity70%Dimethyl Fumarate30%Part D<11 patientsPyrimidine Synthesis Inhibitor0.5%Teriflunomide100%Part D≥16 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”